Companies/Xenon Pharmaceuticals Inc.

Company profile

Xenon Pharmaceuticals Inc.

NASDAQ: XENE · Healthcare · Biotechnology

Canadian filerHQ Burnaby, BCCIK 0001582313Reports USD

#660 of 1,394 Healthcare companies by revenue

EA Score

56C

FH 46DQ 69GM 48SS 74

v0.1 · 65/100 weight · provisional

↑ Altman-Z, balance-sheet leverage · ↓ operating margin, net margin

Methodology →

Revenue TTM

Rev growth YoY (TTM)

-100.0%

Net income (FY)

-$345.9M

Employees

316

Market cap

$4.8B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$7.5M$7.5M2025

Net income-$345.9M-$345.9M2025

Operating income-$373.1M-$373.1M2025

Total assets$633.2M$633.2M2025

Liabilities$51.4M$51.4M2025

Equity$581.8M$581.8M2025

Revenue trend

FY2018 – FY2025 · USD

$311.0k

FY18

$6.8M

FY19

$32.2M

FY20

$18.4M

FY21

$9.4M

FY22

FY25

$7.5M

FY25

Revenue by segment

Filed disclosures · FY2022

By product

License and Service100%

By geography

Not disclosed.

The read

Xenon Pharmaceuticals Inc. booked $7.5M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -4612.1% net margin.

Peers · Healthcare

Definium Therapeutics, Inc.——Alignment Healthcare, Inc.71B 10x Genomics, Inc.67B Indivior Pharmaceuticals Inc67B

Key facts

CEOAndrea DiFabio

SectorHealthcare

IndustryBiotechnology

HeadquartersBurnaby, BC

ExchangeNASDAQ: XENE

Employees316

IPO date2014-11-05

Latest filings

8-K2026-06-03 8-K2026-05-07 10-Q2026-05-07 DEF 14A2026-04-22 8-K2026-04-13 8-K2026-03-13 8-K2026-03-12 8-K2026-03-09

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.